 acelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) reports financial results for the first quarter ended on march 31, 2016. 
 we report net loss of $11 million or $0.24 basic net loss per share as compared to net loss of $10 million or $0.23 basic net loss per share for the first quarter of 2015.    
 we made significant progress in the first quarter on the development of our two product candidates, the sublingual sufentanil sublingual tablet system and the sublingual sufentanil injection system. 
 we initiated two new clinical studies in the first quarter of 2016. 
 the first is an extension of the single dose phase of the single dose study for the sublingual sufentanil system and the second is an open-label study for the sufentanil injection system for the treatment of moderate to severe acute pain following a surgical procedure.    
 we also made progress in the development of the sufentanil injection system and the development of the sufentanil sublingual injection system. 
 we made significant progress in the development of the sublingual suf